Towards translational therapies for multiple system atrophy

[1]  Karin Ackermann,et al.  Progress In Neurobiology , 2016 .

[2]  D. Galasko,et al.  Widespread microRNA dysregulation in multiple system atrophy – disease‐related alteration in miR‐96 , 2014, The European journal of neuroscience.

[3]  W. Poewe,et al.  Rifampicin for multiple system atrophy , 2014, The Lancet Neurology.

[4]  S. Gilman,et al.  Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial , 2014, The Lancet Neurology.

[5]  W. Meissner,et al.  Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy , 2014, Movement disorders : official journal of the Movement Disorder Society.

[6]  E. Masliah,et al.  Antidepressants reduce neuroinflammatory responses and astroglial alpha‐synuclein accumulation in a transgenic mouse model of multiple system atrophy , 2014, Glia.

[7]  G. Halliday,et al.  α-Synucleinopathy phenotypes. , 2014, Parkinsonism & related disorders.

[8]  S. Prusiner,et al.  Transmission of multiple system atrophy prions to transgenic mice , 2013, Proceedings of the National Academy of Sciences.

[9]  B. Bloem,et al.  Update on diffusion MRI in Parkinson's disease and atypical parkinsonism , 2013, Journal of the Neurological Sciences.

[10]  G. Wenning,et al.  Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence , 2013, Experimental Neurology.

[11]  Jiajie Diao,et al.  Properties of native brain α-synuclein , 2013, Nature.

[12]  W. Poewe,et al.  Intact Olfaction in a Mouse Model of Multiple System Atrophy , 2013, PloS one.

[13]  T. Révész,et al.  Identification and Quantification of Oligodendrocyte Precursor Cells in Multiple System Atrophy, Progressive Supranuclear Palsy and Parkinson's Disease , 2013, Brain pathology.

[14]  S. Arawaka,et al.  The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson’s disease: a review of in vivo models , 2013, Reviews in the neurosciences.

[15]  C. Fowler,et al.  Bladder dysfunction in a transgenic mouse model of multiple system atrophy , 2013, Movement disorders : official journal of the Movement Disorder Society.

[16]  W. Poewe,et al.  Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia , 2013, Glia.

[17]  B. Hyman,et al.  Mechanisms of protein seeding in neurodegenerative diseases. , 2013, JAMA neurology.

[18]  Günther Deuschl,et al.  The natural history of multiple system atrophy: a prospective European cohort study , 2013, The Lancet Neurology.

[19]  J. Hardy,et al.  α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? , 2013, Acta Neuropathologica.

[20]  G. Halliday,et al.  FAS-Dependent Cell Death in α-Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy , 2013, PloS one.

[21]  S. Mondello,et al.  Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders , 2013, Front. Neur..

[22]  J. Trojanowski,et al.  Mutations in COQ2 in familial and sporadic multiple-system atrophy. , 2013, The New England journal of medicine.

[23]  M. Frasier,et al.  α-synuclein imaging: a critical need for Parkinson's disease research. , 2013, Journal of Parkinson's disease.

[24]  A. Brunetti,et al.  A randomized clinical trial of lithium in multiple system atrophy , 2013, Journal of Neurology.

[25]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[26]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[27]  P. Novak,et al.  Treatment of multiple system atrophy using intravenous immunoglobulin , 2012, BMC Neurology.

[28]  DelindaA . Johnson,et al.  Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein , 2012, Journal of Neuroimmune Pharmacology.

[29]  W. Oertel,et al.  Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes , 2012, Movement disorders : official journal of the Movement Disorder Society.

[30]  I. Toni,et al.  Reduced parietal connectivity with a premotor writing area in writer's cramp , 2012, Movement disorders : official journal of the Movement Disorder Society.

[31]  N. Stefanova,et al.  The Role of Glia in Alpha-Synucleinopathies , 2012, Molecular Neurobiology.

[32]  W. Poewe,et al.  Is Transcranial Sonography Useful to Distinguish Drug-Induced Parkinsonism From Parkinson ’ s Disease ? , 2012 .

[33]  B. Mollenhauer,et al.  Novel One-step Immunoassays to Quantify α-Synuclein , 2012, The Journal of Biological Chemistry.

[34]  A. Cuadrado,et al.  α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. , 2012, Human molecular genetics.

[35]  Y. Sohn,et al.  A randomized trial of mesenchymal stem cells in multiple system atrophy , 2012, Annals of neurology.

[36]  S. Gilman,et al.  Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? , 2012, Annals of neurology.

[37]  W. Poewe,et al.  Is Transcranial Sonography Useful to Distinguish Scans Without Evidence of Dopaminergic Deficit Patients From Parkinson's Disease? , 2012, Movement disorders : official journal of the Movement Disorder Society.

[38]  A. Björklund,et al.  Alpha-Synuclein Cell-to-Cell Transfer and Seeding in Grafted Dopaminergic Neurons In Vivo , 2012, PloS one.

[39]  K. Jellinger.  The role of α-synuclein in neurodegeneration — An update , 2012 .

[40]  G. Nikkhah,et al.  Behavioral and histological analysis of a partial double‐lesion model of parkinson‐variant multiple system atrophy , 2012, Journal of neuroscience research.

[41]  S. Chen,et al.  The changing phenotype of microglia from homeostasis to disease , 2012, Translational Neurodegeneration.

[42]  V. Moskova-Doumanova,et al.  Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells. , 2012, Tissue & cell.

[43]  J. Winkler,et al.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy , 2012, Experimental Neurology.

[44]  E. Tolosa,et al.  Premotor signs and symptoms of multiple system atrophy , 2012, The Lancet Neurology.

[45]  R. Nussbaum,et al.  α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system , 2012, Journal of Neural Transmission.

[46]  E. Masliah,et al.  Neuronal to oligodendroglial alpha-synuclein redistribution in a double transgenic model of multiple system atrophy , 2012, Neuroreport.

[47]  A. Kraft,et al.  Microglia in the developing brain: a potential target with lifetime effects. , 2012, Neurotoxicology.

[48]  J. Trojanowski,et al.  Phosphorylated α-Synuclein in Parkinson’s Disease , 2012, Science Translational Medicine.

[49]  W. F. Abdo,et al.  CSF α-synuclein does not differentiate between parkinsonian disorders , 2012, Neurobiology of Aging.

[50]  I. Yazawa,et al.  Binding of neuronal α-synuclein to β-III tubulin and accumulation in a model of multiple system atrophy. , 2012, Biochemical and biophysical research communications.

[51]  D. Mann,et al.  Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies , 2012, Neurobiology of Disease.

[52]  J. Trojanowski,et al.  Phosphorylated alpha-Synuclein in Parkinson's Disease , 2012 .

[53]  W. Poewe,et al.  Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model , 2012, Neurotoxicity Research.

[54]  A. Kakita,et al.  Accumulation of histone deacetylase 6, an aggresome‐related protein, is specific to Lewy bodies and glial cytoplasmic inclusions , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.

[55]  E. Masliah,et al.  Multiple system atrophy: a clinical and neuropathological perspective , 2011, Trends in Neurosciences.

[56]  Sonja W. Scholz,et al.  Genetic players in multiple system atrophy: unfolding the nature of the beast , 2011, Neurobiology of Aging.

[57]  P. Brundin,et al.  A deadly spread: cellular mechanisms of α-synuclein transfer , 2011, Cell Death and Differentiation.

[58]  E. Masliah,et al.  Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives , 2011, Neuroscience Research.

[59]  W. Poewe,et al.  Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. , 2011, The American journal of pathology.

[60]  A. Capasso,et al.  Neuroinflamm-aging and neurodegenerative diseases: an overview. , 2011, CNS & neurological disorders drug targets.

[61]  P. Lee,et al.  Neuroprotective Effect of Human Mesenchymal Stem Cells in an Animal Model of Double Toxin-Induced Multiple System Atrophy Parkinsonism , 2011, Cell transplantation.

[62]  Ulrich Pfisterer,et al.  Direct conversion of human fibroblasts to dopaminergic neurons , 2011, Proceedings of the National Academy of Sciences.

[63]  G. Wenning,et al.  Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection , 2011, PloS one.

[64]  K. Jellinger,et al.  Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts , 2011, Acta Neuropathologica.

[65]  M. Cookson,et al.  DJ-1 regulation of mitochondrial function and autophagy through oxidative stress , 2011, Autophagy.

[66]  E. Masliah,et al.  Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.

[67]  Yan-ling Zhang,et al.  HDAC6 regulates aggresome‐autophagy degradation pathway of α‐synuclein in response to MPP+‐induced stress , 2011, Journal of neurochemistry.

[68]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[69]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[70]  P. Brundin,et al.  α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. , 2011, The Journal of clinical investigation.

[71]  R. Akundi,et al.  Increased Mitochondrial Calcium Sensitivity and Abnormal Expression of Innate Immunity Genes Precede Dopaminergic Defects in Pink1-Deficient Mice , 2011, PloS one.

[72]  Melinda E. Lull,et al.  Microglial activation and chronic neurodegeneration , 2010, Neurotherapeutics.

[73]  Igor Tsigelny,et al.  Cell-to-cell transmission of non-prion protein aggregates , 2010, Nature Reviews Neurology.

[74]  Y. Itoyama,et al.  Role of TPPP/p25 on α-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy , 2010, Neurochemistry International.

[75]  Christian Hansen,et al.  Are synucleinopathies prion-like disorders? , 2010, The Lancet Neurology.

[76]  K. Chung,et al.  New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease. , 2010, Biochimica et biophysica acta.

[77]  B. Mollenhauer,et al.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.

[78]  M. Schocke,et al.  Differenzialdiagnose der Parkinson-Syndrome mittels MRT , 2010, Der Nervenarzt.

[79]  Aneeka M Hancock,et al.  Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease , 2010, Neuroscience Letters.

[80]  W. Poewe,et al.  Targeted overexpression of human α-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure , 2010, Experimental Neurology.

[81]  Hitoshi Takahashi,et al.  Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain , 2010, Acta Neuropathologica.

[82]  E. Masliah,et al.  Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors , 2010, The Journal of Neuroscience.

[83]  E. Masliah,et al.  Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy , 2010, Neuroreport.

[84]  A. M. Martín-Moreno,et al.  Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease , 2010, Glia.

[85]  C. Colton,et al.  Assessing activation states in microglia. , 2010, CNS & neurological disorders drug targets.

[86]  K. Jellinger,et al.  Papp–Lantos inclusions and the pathogenesis of multiple system atrophy: an update , 2010, Acta Neuropathologica.

[87]  J. Taylor,et al.  HDAC6 controls autophagosome maturation essential for ubiquitin‐selective quality‐control autophagy , 2010, The EMBO journal.

[88]  M. Diamond,et al.  Prion-like mechanisms in neurodegenerative diseases , 2010, Nature Reviews Neuroscience.

[89]  Alexander Gerhard,et al.  Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) , 2010, Movement disorders : official journal of the Movement Disorder Society.

[90]  E. Masliah,et al.  Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies* , 2010, The Journal of Biological Chemistry.

[91]  O. Lindvall,et al.  Stem cells in human neurodegenerative disorders--time for clinical translation? , 2010, The Journal of clinical investigation.

[92]  K. Leenders,et al.  [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? , 2010, Parkinsonism & related disorders.

[93]  M. Schocke,et al.  [Differential diagnosis of parkinsonian syndromes using MRI]. , 2010, Der Nervenarzt.

[94]  G. Wenning,et al.  Multiple system atrophy: an update , 2009, The Lancet Neurology.

[95]  N. Quinn,et al.  A validation exercise on the new consensus criteria for multiple system atrophy , 2009, Movement disorders : official journal of the Movement Disorder Society.

[96]  Nicholas W. Wood,et al.  Genetic Variants of the α-Synuclein Gene SNCA Are Associated with Multiple System Atrophy , 2009, PloS one.

[97]  W. Poewe,et al.  Striatal transplantation for multiple system atrophy — Are grafts affected by α-synucleinopathy? , 2009, Experimental Neurology.

[98]  E. Masliah,et al.  Mitochondrial inhibitor 3‐nitroproprionic acid enhances oxidative modification of alpha‐synuclein in a transgenic mouse model of multiple system atrophy , 2009, Journal of neuroscience research.

[99]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[100]  J. Ovádi,et al.  An unstructured protein with destructive potential: TPPP/p25 in neurodegeneration , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[101]  G. Wenning,et al.  Recent developments in multiple system atrophy , 2009, Journal of Neurology.

[102]  W. Poewe,et al.  Striatal transplantation in a rodent model of multiple system atrophy: Effects on L‐Dopa response , 2009, Journal of neuroscience research.

[103]  Sonja W. Scholz,et al.  SNCA variants are associated with increased risk for multiple system atrophy , 2009, Annals of neurology.

[104]  O. Lindvall,et al.  Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. , 2009, Trends in pharmacological sciences.

[105]  Xiaomin Su,et al.  Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity , 2009, Neurotoxicity Research.

[106]  C. Richter-Landsberg,et al.  α-Synuclein Aggregation and Ser-129 Phosphorylation-dependent Cell Death in Oligodendroglial Cells* , 2009, Journal of Biological Chemistry.

[107]  I. Yazawa,et al.  Microtubule depolymerization suppresses alpha-synuclein accumulation in a mouse model of multiple system atrophy. , 2009, The American journal of pathology.

[108]  C. Richter-Landsberg,et al.  α-Synuclein Promotes the Recruitment of Tau to Protein Inclusions in Oligodendroglial Cells: Effects of Oxidative and Proteolytic Stress , 2009, Journal of Molecular Neuroscience.

[109]  Y. Agid,et al.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study , 2008, Brain : a journal of neurology.

[110]  Xiaomin Su,et al.  Synuclein activates microglia in a model of Parkinson's disease , 2008, Neurobiology of Aging.

[111]  G. Halliday,et al.  LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions , 2008, Acta Neuropathologica.

[112]  O. Lindvall,et al.  Research in motion: the enigma of Parkinson's disease pathology spread , 2008, Nature Reviews Neuroscience.

[113]  K. Jellinger,et al.  Multiple system atrophy: A primary oligodendrogliopathy , 2008, Annals of neurology.

[114]  E. Masliah,et al.  Rifampicin reduces &agr;-synuclein in a transgenic mouse model of multiple system atrophy , 2008, Neuroreport.

[115]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[116]  He-Jin Lee,et al.  Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. , 2008, Biochemical and biophysical research communications.

[117]  H. Sasaki,et al.  Associations between multiple system atrophy and polymorphisms of SLC1A4, SQSTM1, and EIF4EBP1 Genes , 2008, Movement disorders : official journal of the Movement Disorder Society.

[118]  P. Mcgeer,et al.  α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia , 2008, Neurobiology of Aging.

[119]  Ninds Net-Pd Investigators.  A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results , 2008, Clinical neuropharmacology.

[120]  K. Huh,et al.  Autologous Mesenchymal Stem Cell Therapy Delays the Progression of Neurological Deficits in Patients With Multiple System Atrophy , 2008, Clinical pharmacology and therapeutics.

[121]  N. Quinn,et al.  Are Trials of Intravascular Infusions of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy Currently Justified, and Are They Effective? , 2008, Clinical pharmacology and therapeutics.

[122]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[123]  M. Vidailhet,et al.  Risk factors of multiple system atrophy: A case‐control study in French patients , 2008, Movement disorders : official journal of the Movement Disorder Society.

[124]  W. Poewe,et al.  Rasagiline is neuroprotective in a transgenic model of multiple system atrophy , 2008, Experimental Neurology.

[125]  Satoshi Orimo,et al.  Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease , 2008 .

[126]  T. Amino,et al.  Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. , 2008, Journal of medical and dental sciences.

[127]  H. Gendelman,et al.  Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities , 2008, Journal of Neuroimmune Pharmacology.

[128]  A. Kakita,et al.  Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. , 2008, Brain : a journal of neurology.

[129]  J. Jankovic,et al.  Potential outcome measures and trial design issues for multiple system atrophy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[130]  J. Trojanowski,et al.  Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy , 2007, Neuropathology and applied neurobiology.

[131]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[132]  W. Poewe,et al.  Microglial activation mediates neurodegeneration related to oligodendroglial α‐synucleinopathy: Implications for multiple system atrophy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[133]  P. Højrup,et al.  p25α Relocalizes in Oligodendroglia from Myelin to Cytoplasmic Inclusions in Multiple System Atrophy , 2007 .

[134]  T. Ozawa.  Morphological substrate of autonomic failure and neurohormonal dysfunction in multiple system atrophy: impact on determining phenotype spectrum , 2007, Acta Neuropathologica.

[135]  E. Tolosa,et al.  Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[136]  P. Bauer,et al.  Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson’s disease , 2007, Journal of Neural Transmission.

[137]  C. Ide,et al.  Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients , 2007, Movement disorders : official journal of the Movement Disorder Society.

[138]  I. Kanazawa,et al.  Multiplex families with multiple system atrophy. , 2007, Archives of neurology.

[139]  M. Farrer,et al.  Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication , 2007, Neurology.

[140]  H. Budka,et al.  Accumulation of Hsc70 and Hsp70 in glial cytoplasmic inclusions in patients with multiple system atrophy , 2007, Brain Research.

[141]  A. Gitler,et al.  Prime Time for α-Synuclein , 2007, The Journal of Neuroscience.

[142]  W. Poewe,et al.  Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[143]  C. Mathias,et al.  Progression of dysautonomia in multiple system atrophy: a prospective study of self‐perceived impairment , 2007, European journal of neurology.

[144]  P. Højrup,et al.  p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. , 2007, The American journal of pathology.

[145]  S. Gilman,et al.  PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[146]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[147]  J. Parisi,et al.  Differential involvement of hypothalamic vasopressin neurons in multiple system atrophy. , 2006, Brain : a journal of neurology.

[148]  Yoav Ben-Shlomo,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Clinical Autonomic Research.

[149]  A. Young,et al.  Absence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia , 2005, Journal of Neural Transmission.

[150]  Makoto Hashimoto,et al.  Neurological and Neurodegenerative Alterations in a Transgenic Mouse Model Expressing Human α-Synuclein under Oligodendrocyte Promoter: Implications for Multiple System Atrophy , 2005, The Journal of Neuroscience.

[151]  G. Kollias,et al.  Apoptosis of Oligodendrocytes via Fas and TNF-R1 Is a Key Event in the Induction of Experimental Autoimmune Encephalomyelitis1 , 2005, The Journal of Immunology.

[152]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[153]  J. Trojanowski,et al.  Mouse Model of Multiple System Atrophy α-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration , 2005, Neuron.

[154]  Werner Poewe,et al.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. , 2005, The American journal of pathology.

[155]  Daniel Otzen,et al.  p25α Stimulates α-Synuclein Aggregation and Is Co-localized with Aggregated α-Synuclein in α-Synucleinopathies* , 2005, Journal of Biological Chemistry.

[156]  A. Young,et al.  Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. , 2005, Journal of neural transmission.

[157]  K. Jellinger,et al.  The role of alpha-synuclein in the pathogenesis of multiple system atrophy. , 2005, Acta neuropathologica.

[158]  C. Scherfler,et al.  Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy) , 2005, Journal of Neural Transmission.

[159]  C. Scherfler,et al.  Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice , 2005, Journal of Neural Transmission.

[160]  K. Jellinger,et al.  The role of α-synuclein in the pathogenesis of multiple system atrophy , 2005, Acta Neuropathologica.

[161]  H. Budka,et al.  Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies , 2004, Neurobiology of Disease.

[162]  K. Wakabayashi,et al.  A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy , 2004, Neuropathology and applied neurobiology.

[163]  W. Poewe,et al.  Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration , 2004, Journal of neuroscience research.

[164]  Niall P Quinn,et al.  The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. , 2004, Brain : a journal of neurology.

[165]  R. Mrak,et al.  Microglia and neuroinflammation: a pathological perspective , 2004 .

[166]  G. Deuschl,et al.  Probable multiple system atrophy in a German family , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[167]  B. Bioulac,et al.  MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration , 2004, Experimental Neurology.

[168]  E. Benarroch.  Brainstem in Multiple System Atrophy: Clinicopathological Correlations , 2003, Cellular and Molecular Neurobiology.

[169]  T. Iwatsubo,et al.  Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. , 2004, Acta neuropathologica.

[170]  K. Hasegawa,et al.  Argyrophilic glial intracytoplasmic inclusions in multiple system atrophy: immunocytochemical and ultrastructural study , 2004, Acta Neuropathologica.

[171]  T. Iwatsubo,et al.  Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy , 2004, Acta Neuropathologica.

[172]  Robert Layfield,et al.  Oligodendrocytes Promote Neuronal Survival and Axonal Length by Distinct Intracellular Mechanisms: A Novel Role for Oligodendrocyte-Derived Glial Cell Line-Derived Neurotrophic Factor , 2003, The Journal of Neuroscience.

[173]  T. Montine,et al.  Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy , 2003, Acta Neuropathologica.

[174]  K. Jellinger,et al.  Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy) , 2003, Acta Neuropathologica.

[175]  J. Culvenor,et al.  α-synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy , 2003, Experimental Neurology.

[176]  J. Culvenor,et al.  alpha-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. , 2003, Experimental neurology.

[177]  H. Lüders,et al.  Systemic Overexpression of the α1B‐Adrenergic Receptor in Mice: An Animal Model of Epilepsy , 2002 .

[178]  P. Gonzalez-Cabrera,et al.  Mice expressing the α1B‐adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation , 2002, Journal of neurochemistry.

[179]  B. Bioulac,et al.  Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation , 2002, Neuroscience.

[180]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[181]  DelindaA . Johnson,et al.  Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice , 2002, Journal of neurochemistry.

[182]  Y. Abe,et al.  Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. , 2002, Brain : a journal of neurology.

[183]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[184]  E. Benarroch.  New findings on the neuropathology of multiple system atrophy , 2002, Autonomic Neuroscience.

[185]  W. Spooren,et al.  Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. , 2002, EMBO reports.

[186]  H. Lüders,et al.  Systemic overexpression of the alpha 1B-adrenergic receptor in mice: an animal model of epilepsy. , 2002, Epilepsia.

[187]  D. Burn,et al.  Multiple system atrophy: cellular and molecular pathology , 2001, Molecular pathology : MP.

[188]  A Compston,et al.  A role for oligodendrocyte‐derived IGF‐1 in trophic support of cortical neurons , 2001, Glia.

[189]  S. Tsuji,et al.  Analysis of the expression level of α-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy , 2001, Acta Neuropathologica.

[190]  H U Rehman,et al.  Multiple system atrophy , 2001, Postgraduate medical journal.

[191]  C. Scherfler,et al.  No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy) , 2001, Neuroscience.

[192]  I. Ghorayeb,et al.  Simultaneous Intrastriatal 6-Hydroxydopamine and Quinolinic Acid Injection: A Model of Early-Stage Striatonigral Degeneration , 2001, Experimental Neurology.

[193]  T. Iwatsubo,et al.  Co-localization of α-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration , 2001, Acta Neuropathologica.

[194]  Scott Sands,et al.  Overexpression of the α1B-adrenergic receptor causes apoptotic neurodegeneration: Multiple system atrophy , 2000, Nature Medicine.

[195]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[196]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[197]  T. Montine,et al.  Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of α‐Synuclein Permutations in Multiple System Atrophy , 2000, Journal of neuropathology and experimental neurology.

[198]  I. Ghorayeb,et al.  Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy) , 2000, Neuroscience.

[199]  M. Levivier,et al.  Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy) , 2000, Experimental Neurology.

[200]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[201]  R. Marconi,et al.  Smoking habits in multiple system atrophy and progressive supranuclear palsy , 2000, Neurology.

[202]  D. Morilak,et al.  Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. , 2000, Nature medicine.

[203]  C. Scherfler,et al.  Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts , 1999, Neuroscience.

[204]  Y. Ahn,et al.  Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. , 1999, Journal of immunology.

[205]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[206]  J. Jankovic,et al.  Multiple system atrophy: the putative causative role of environmental toxins. , 1999, Archives of neurology.

[207]  I. Shoulson,et al.  Experimental therapeutics of neurodegenerative disorders: unmet needs. , 1998, Science.

[208]  P. Mcgeer,et al.  Myelin degeneration in multiple system atrophy detected by unique antibodies. , 1998, The American journal of pathology.

[209]  K. Schmid,et al.  Cell Death Mechanisms in Multiple System Atrophy , 1998, Journal of neuropathology and experimental neurology.

[210]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[211]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[212]  Hitoshi Takahashi,et al.  Multiple system atrophy with severe involvement of the motor cortical areas and cerebral white matter , 1998, Journal of the Neurological Sciences.

[213]  J. Parisi,et al.  Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure , 1998, Annals of neurology.

[214]  R A Crowther,et al.  Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.

[215]  K. Jellinger.  Neuropathology of movement disorders. , 1998, Neurosurgery clinics of North America.

[216]  Kazuko Hasegawa,et al.  The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems , 1997, Acta Neuropathologica.

[217]  H. Kusaka,et al.  Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy , 1996, Neurology.

[218]  C. Marsden,et al.  Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration , 1996, Movement disorders : official journal of the Movement Disorder Society.

[219]  N P Quinn,et al.  Olivopontocerebellar pathology in multiple system atrophy , 1996, Movement disorders : official journal of the Movement Disorder Society.

[220]  P. Sanberg,et al.  Systemic 3-nitropropionic acid: Behavioral deficits and striatal damage in adult rats , 1995, Brain Research Bulletin.

[221]  Toshio Shimizu,et al.  Decrease of medullary catecholaminergic neurons in multiple system atrophy and Parkinson's disease and their preservation in amyotrophic lateral sclerosis , 1995, Journal of the Neurological Sciences.

[222]  J. Cano,et al.  Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system , 1995, Brain Research.

[223]  N P Quinn,et al.  Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. , 1994, Brain : a journal of neurology.

[224]  P. Lantos,et al.  The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. , 1994, Brain : a journal of neurology.

[225]  G K Wenning,et al.  "Minimal change" multiple system atrophy. , 1994, Movement disorders : official journal of the Movement Disorder Society.

[226]  B. Rosen,et al.  1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism , 1992, Journal of neurochemistry.

[227]  K. Imahori,et al.  A novel brain‐specific 25 kDa protein (p25) is phosphorylated by a Ser/Thr‐Pro kinase (TPK II) from tau protein kinase fractions , 1991, FEBS letters.

[228]  H. Yamaguchi,et al.  Oligodendroglial Microtubular Tangles in Olivopontocerebellar Atrophy , 1990, Journal of neuropathology and experimental neurology.

[229]  Peter L. Lantos,et al.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.